Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The analytes d-threo-methylphenidate and l-threo-methylphenidate and their internal standard methylphenidate-d9 were extracted from a 0.200 mL aliquot of human EDTA K2 plasma using an automated liquid–liquid extraction.
In the USA a wide range of pharmacological treatments are approved for use in adults, including Atomoxetine (ATX), Methylphenidate (MPH), DexMethylphenidate, and various amphetamines (Castells et al., 2011; Fredriksen et al., 2013).
Ritalin LA® and Focalin XR® (both Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA) use Spheroidal Oral Drug Absorption System (SODAS®) technology to provide 50% of the MPH dose immediately and 50% as extended release [6,7].